Insulet Co. (NASDAQ:PODD) Receives $277.13 Consensus Target Price from Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have been given an average rating of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $277.13.

A number of analysts have weighed in on PODD shares. TD Cowen increased their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Morgan Stanley increased their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Citigroup lifted their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Barclays increased their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Finally, JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th.

Insulet Trading Down 1.6 %

Shares of NASDAQ PODD opened at $283.08 on Friday. The stock has a market capitalization of $19.86 billion, a P/E ratio of 48.47, a PEG ratio of 3.61 and a beta of 1.23. The stock’s 50 day moving average price is $270.27 and its two-hundred day moving average price is $241.58. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet has a 52-week low of $160.19 and a 52-week high of $289.46.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.13. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period in the prior year, the company posted $0.71 EPS. On average, analysts anticipate that Insulet will post 3.22 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

Several institutional investors have recently modified their holdings of PODD. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet during the fourth quarter worth $36,000. Venturi Wealth Management LLC lifted its holdings in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the last quarter. SRS Capital Advisors Inc. lifted its holdings in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 56 shares during the last quarter. Finally, Friedenthal Financial acquired a new position in shares of Insulet in the 4th quarter valued at $57,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.